NCT06176768

A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3972406 in Adults With Moderate-to-Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to determine the efficacy and safety of LY3972406 in adult participants with moderate-to-severe plaque psoriasis.

Conditions

• Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	LY3972406	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2023-12-06
• Primary completion: 2025-04-01
• Completion: 2025-05-06
• First posted: 2023-12-20
• Last updated: 2025-10-15
• Results posted: 2025-10-15

Locations

12 sites across 1 country: United States

Regulatory

• FDA-regulated drug study